-
1 Comment
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 15.6% above its 200 day moving average.
From a valuation standpoint, the stock is 96.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.4.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd's total revenue sank by 16.5% to $338M since the same quarter in the previous year.
Its net income has dropped by 24.6% to $80M since the same quarter in the previous year.
Finally, its free cash flow fell by 3.8% to $75M since the same quarter in the previous year.
Based on the above factors, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd gets an overall score of 2/5.
| ISIN | CNE1000000W4 |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | HK |
| CurrencyCode | HKD |
| Market Cap | 7B |
|---|---|
| PE Ratio | 65.25 |
| Beta | 0.33 |
| Target Price | 7.48 |
| Dividend Yield | 2.1% |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; Trop2-BB05 ADC that is in Phase I clinical trial for tumors; DLL3-BB05 ADC, which is in phase I clinical trial for tumors; and HER2 ADC that is in phase I clinical study for tumors. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which have complected Phase IV clinical trial; and Aminolevulinic acid " CIN, which have complected phase II clinical trials for cervical diseases infected by HPV; Aminolevulinic acid " AK, which is in phase II clinical trials for Actinic keratosis; Aminolevulinic acid " acne, which is in phase II clinical trials for Acne; Aminolevulinic acid " gliomas for Surgical visualization of gliomas; Aminolevulinic acid " bladder for Surgical visualization of bladder cancer; and Aminolevulinic acid " breast that has obtained phase I clinical trial approval for Surgical visualization of breast cancer. In addition, it offers Osmotic pump technology platform drugs, which includes Controlled-release carbidopa/levodopa Tablets which have complected phase II clinical trials for Early Parkinson's disease; and Obeticholic acid for the treatment of Hepatobiliary diseases/ Autoimmune diseases. Further, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 1349.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
